4.48
+0.33(+7.95%)
Currency In USD
| Previous Close | 4.15 |
| Open | 4.17 |
| Day High | 4.54 |
| Day Low | 4.17 |
| 52-Week High | 17.38 |
| 52-Week Low | 3.82 |
| Volume | 1.36M |
| Average Volume | 224,935 |
| Market Cap | 42.32M |
| PE | -0.58 |
| EPS | -7.74 |
| Moving Average 50 Days | 5.01 |
| Moving Average 200 Days | 5.86 |
| Change | 0.33 |
If you invested $1000 in Verrica Pharmaceuticals Inc. (VRCA) since IPO date, it would be worth $256 as of October 20, 2025 at a share price of $4.48. Whereas If you bought $1000 worth of Verrica Pharmaceuticals Inc. (VRCA) shares 5 years ago, it would be worth $534.61 as of October 20, 2025 at a share price of $4.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
GlobeNewswire Inc.
1 hours ago
– EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in the U.S. and Japan are adequate to support a filing for the approval of YCANTH® in the EU and that no additional Phase 3 s
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
GlobeNewswire Inc.
Oct 07, 2025 8:05 PM GMT
WEST CHESTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced t
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
GlobeNewswire Inc.
Sep 19, 2025 12:00 PM GMT
– Approval triggers $10 million cash milestone payment to Verrica – – YCANTH® approval in Japan addresses significant unmet need of patients with molluscum – – Verrica maintains ownership of global rights to YCANTH for all indications in all territor